IBDEI2M0 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41673,0)
 ;;=I25.111^^155^2062^7
 ;;^UTILITY(U,$J,358.3,41673,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41673,1,3,0)
 ;;=3^Athscl hrt disease of native cor art w ang pctrs w spasm
 ;;^UTILITY(U,$J,358.3,41673,1,4,0)
 ;;=4^I25.111
 ;;^UTILITY(U,$J,358.3,41673,2)
 ;;=^5007109
 ;;^UTILITY(U,$J,358.3,41674,0)
 ;;=I25.118^^155^2062^8
 ;;^UTILITY(U,$J,358.3,41674,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41674,1,3,0)
 ;;=3^Athscl hrt disease of native cor art w oth ang pctrs
 ;;^UTILITY(U,$J,358.3,41674,1,4,0)
 ;;=4^I25.118
 ;;^UTILITY(U,$J,358.3,41674,2)
 ;;=^5007110
 ;;^UTILITY(U,$J,358.3,41675,0)
 ;;=I25.119^^155^2062^9
 ;;^UTILITY(U,$J,358.3,41675,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41675,1,3,0)
 ;;=3^Athscl hrt disease of native cor art w unsp ang pctrs
 ;;^UTILITY(U,$J,358.3,41675,1,4,0)
 ;;=4^I25.119
 ;;^UTILITY(U,$J,358.3,41675,2)
 ;;=^5007111
 ;;^UTILITY(U,$J,358.3,41676,0)
 ;;=I25.110^^155^2062^10
 ;;^UTILITY(U,$J,358.3,41676,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41676,1,3,0)
 ;;=3^Athscl hrt disease of native cor art w unstable ang pctrs
 ;;^UTILITY(U,$J,358.3,41676,1,4,0)
 ;;=4^I25.110
 ;;^UTILITY(U,$J,358.3,41676,2)
 ;;=^5007108
 ;;^UTILITY(U,$J,358.3,41677,0)
 ;;=I25.10^^155^2062^11
 ;;^UTILITY(U,$J,358.3,41677,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41677,1,3,0)
 ;;=3^Athscl hrt disease of native cor art w/o ang pctrs
 ;;^UTILITY(U,$J,358.3,41677,1,4,0)
 ;;=4^I25.10
 ;;^UTILITY(U,$J,358.3,41677,2)
 ;;=^5007107
 ;;^UTILITY(U,$J,358.3,41678,0)
 ;;=I48.0^^155^2062^28
 ;;^UTILITY(U,$J,358.3,41678,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41678,1,3,0)
 ;;=3^Paroxysmal atrial fibrillation
 ;;^UTILITY(U,$J,358.3,41678,1,4,0)
 ;;=4^I48.0
 ;;^UTILITY(U,$J,358.3,41678,2)
 ;;=^90473
 ;;^UTILITY(U,$J,358.3,41679,0)
 ;;=I42.9^^155^2062^13
 ;;^UTILITY(U,$J,358.3,41679,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41679,1,3,0)
 ;;=3^Cardiomyopathy, unspecified
 ;;^UTILITY(U,$J,358.3,41679,1,4,0)
 ;;=4^I42.9
 ;;^UTILITY(U,$J,358.3,41679,2)
 ;;=^5007200
 ;;^UTILITY(U,$J,358.3,41680,0)
 ;;=I50.42^^155^2062^14
 ;;^UTILITY(U,$J,358.3,41680,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41680,1,3,0)
 ;;=3^Chronic combined systolic and diastolic hrt fail
 ;;^UTILITY(U,$J,358.3,41680,1,4,0)
 ;;=4^I50.42
 ;;^UTILITY(U,$J,358.3,41680,2)
 ;;=^5007249
 ;;^UTILITY(U,$J,358.3,41681,0)
 ;;=I50.32^^155^2062^15
 ;;^UTILITY(U,$J,358.3,41681,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41681,1,3,0)
 ;;=3^Chronic diastolic (congestive) heart failure
 ;;^UTILITY(U,$J,358.3,41681,1,4,0)
 ;;=4^I50.32
 ;;^UTILITY(U,$J,358.3,41681,2)
 ;;=^5007245
 ;;^UTILITY(U,$J,358.3,41682,0)
 ;;=J44.1^^155^2062^16
 ;;^UTILITY(U,$J,358.3,41682,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41682,1,3,0)
 ;;=3^Chronic obstructive pulmonary disease w (acute) exacerbation
 ;;^UTILITY(U,$J,358.3,41682,1,4,0)
 ;;=4^J44.1
 ;;^UTILITY(U,$J,358.3,41682,2)
 ;;=^5008240
 ;;^UTILITY(U,$J,358.3,41683,0)
 ;;=J44.9^^155^2062^17
 ;;^UTILITY(U,$J,358.3,41683,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41683,1,3,0)
 ;;=3^Chronic obstructive pulmonary disease, unspecified
 ;;^UTILITY(U,$J,358.3,41683,1,4,0)
 ;;=4^J44.9
 ;;^UTILITY(U,$J,358.3,41683,2)
 ;;=^5008241
 ;;^UTILITY(U,$J,358.3,41684,0)
 ;;=I50.22^^155^2062^18
 ;;^UTILITY(U,$J,358.3,41684,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41684,1,3,0)
 ;;=3^Chronic systolic (congestive) heart failure
